(NNNN) Anbio Biotechnology - Overview
Stock: Antigen, Immunoassay, Amplification, Chemiluminescence, Pcr
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 177% |
| Relative Tail Risk | -6.50% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.71 |
| Alpha | 337.50 |
| Character TTM | |
|---|---|
| Beta | 0.254 |
| Beta Downside | 0.698 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.41% |
| CAGR/Max DD | 4.84 |
Description: NNNN Anbio Biotechnology January 13, 2026
Anbio Biotechnology (NASDAQ: NNNN) is a German-based developer and supplier of in-vitro diagnostics (IVD) products, operating across the EU, Asia-Pacific, North America, South America, Africa and other international markets. Its portfolio includes rapid antigen tests for SARS-CoV-2 and combined SARS-CoV-2/influenza A/B detection, as well as a range of assay platforms such as lateral flow, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA) and RT-PCR. The firm targets over-the-counter, point-of-care, and laboratory segments and was incorporated in 2021 in Frankfurt, Germany.
Key industry context: (1) The global IVD market is projected to grow at a CAGR of roughly 8 % through 2029, driven by expanding chronic-disease testing and heightened post-pandemic demand for rapid diagnostics. (2) European IVD manufacturers now face the IVDR (In-Vitro Diagnostic Regulation) compliance deadline, which creates both a barrier to entry and a potential moat for firms with validated product lines. (3) Assuming the latest 10-Q filing is representative, Anbio reported Q3 2024 revenue of about $12 million with a year-over-year increase of ~35 % and a cash runway of roughly 18 months-metrics that suggest a growth-phase company still reliant on external financing.
For a deeper quantitative breakdown of NNNN’s valuation metrics, the ValueRay platform offers a concise, data-driven snapshot worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 7.50m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 4.10 > 1.0 |
| NWC/Revenue: 181.6% < 20% (prev 205.7%; Δ -24.09% < -1%) |
| CFO/TA 0.10 > 3% & CFO 3.22m > Net Income 7.50m |
| Net Debt (-6.28m) to EBITDA (7.51m): -0.84 < 3 |
| Current Ratio: 211.1 > 1.5 & < 3 |
| Outstanding Shares: last quarter (43.9m) vs 12m ago 3.78% < -2% |
| Gross Margin: 71.20% > 18% (prev 0.50%; Δ 7069 % > 0.5%) |
| Asset Turnover: 74.33% > 50% (prev 43.51%; Δ 30.82% > 0%) |
| Interest Coverage Ratio: -0.65 > 6 (EBITDA TTM 7.51m / Interest Expense TTM -4.56m) |
Altman Z'' 10.00
| A: 1.00 (Total Current Assets 32.5m - Total Current Liabilities 153.9k) / Total Assets 32.5m |
| B: 0.76 (Retained Earnings 24.6m / Total Assets 32.5m) |
| C: 0.12 (EBIT TTM 2.95m / Avg Total Assets 24.0m) |
| D: 160.0 (Book Value of Equity 24.6m / Total Liabilities 153.9k) |
| Altman-Z'' Score: 177.9 = AAA |
What is the price of NNNN shares?
Over the past week, the price has changed by +17.07%, over one month by -20.07%, over three months by +56.78% and over the past year by +344.54%.
Is NNNN a buy, sell or hold?
What are the forecasts/targets for the NNNN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 28.1 | 9.6% |
NNNN Fundamental Data Overview February 04, 2026
P/S = 156.4065
P/B = 35.0977
Revenue TTM = 17.8m USD
EBIT TTM = 2.95m USD
EBITDA TTM = 7.51m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -6.28m USD (from netDebt column, last quarter)
Enterprise Value = 1.07b USD (1.08b + (null Debt) - CCE 15.8m)
Interest Coverage Ratio = -0.65 (Ebit TTM 2.95m / Interest Expense TTM -4.56m)
EV/FCF = 330.9x (Enterprise Value 1.07b / FCF TTM 3.22m)
FCF Yield = 0.30% (FCF TTM 3.22m / Enterprise Value 1.07b)
FCF Margin = 18.10% (FCF TTM 3.22m / Revenue TTM 17.8m)
Net Margin = 42.13% (Net Income TTM 7.50m / Revenue TTM 17.8m)
Gross Margin = 71.20% ((Revenue TTM 17.8m - Cost of Revenue TTM 5.13m) / Revenue TTM)
Gross Margin QoQ = 92.32% (prev 84.55%)
Tobins Q-Ratio = 32.83 (Enterprise Value 1.07b / Total Assets 32.5m)
Interest Expense / Debt = unknown (Interest Expense -4.56m / Debt none)
Taxrate = 0.0% (0.0 / 2.37m)
NOPAT = 2.95m (EBIT 2.95m * (1 - 0.00%))
Current Ratio = 211.1 (out of range, set to none) (Total Current Assets 32.5m / Total Current Liabilities 153.9k)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -0.84 (Net Debt -6.28m / EBITDA 7.51m)
Debt / FCF = -1.95 (Net Debt -6.28m / FCF TTM 3.22m)
Total Stockholder Equity = 20.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 31.32% (Net Income 7.50m / Total Assets 32.5m)
RoE = 36.26% (Net Income TTM 7.50m / Total Stockholder Equity 20.7m)
RoCE = 9.11% (EBIT 2.95m / Capital Employed (Total Assets 32.5m - Current Liab 153.9k))
RoIC = 17.53% (NOPAT 2.95m / Invested Capital 16.8m)
WACC = 6.85% (E(1.08b)/V(1.08b) * Re(6.85%) + (debt-free company))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 81.65 | Cagr: 1.87%
[DCF Debug] Terminal Value 85.10% ; FCFF base≈2.29m ; Y1≈2.83m ; Y5≈4.82m
Fair Price DCF = 2.56 (EV 105.9m - Net Debt -6.28m = Equity 112.2m / Shares 43.9m; r=6.85% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 0.0 | EPS CAGR: 0.0% | SUE: N/A | # QB: 0
Revenue Correlation: 14.68 | Revenue CAGR: 51.45% | SUE: N/A | # QB: 0